Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib - 24/04/13
Doi : 10.1016/j.jaad.2009.11.589
Theognosia Vergou, MD a, ⁎ 
, Alexander J. Stratigos, MD, PhD a, Eleni M. Karapanagiotou, MD b, Athina E. Matekovits, MD a, Kalliopi D. Dilana, MD b, Sotirios Tsimboukis, MD b, Christina Antoniou, MD, PhD a, Vassiliki Chasapi, MD a, Kostas N. Syrigos, MD, PhD b
, Alexander J. Stratigos, MD, PhD a, Eleni M. Karapanagiotou, MD b, Athina E. Matekovits, MD a, Kalliopi D. Dilana, MD b, Sotirios Tsimboukis, MD b, Christina Antoniou, MD, PhD a, Vassiliki Chasapi, MD a, Kostas N. Syrigos, MD, PhD b a First Department of Dermatology, University of Athens Medical School, Andreas Sygros Hospital, Athens, Greece
b Oncology Unit, Third Department of Medicine, Athens University School of Medicine, Athens, Greece
Correspondence to: Theognosia Vergou, MD, Andreas Sygros Hospital for Skin and Venereal Diseases, First Department of Dermatology, University of Athens Medical School, Ionos Dragoumi 5, 16121, Kaisariani, Athens, Greece| Funding sources: None. |
|
| Conflicts of interest: None declared. |
© 2010
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 63 - N° 2
P. e56-e58 - août 2010 Retour au numéro
Article précédent
- Cutaneous epithelioid angiosarcoma occurring at a peristomal site
- Chris Kon Fessa, Raghwa Sharma, Pablo Fernández-Peñas
- Epidermal growth factor receptor inhibition with erlotinib for palmoplantar keratoderma
- Brandi M. Kenner-Bell, Amy S. Paller, Mario E. Lacouture
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?